However, considering that KRAS activating mutation is very frequent in NSCLC, accounting for about 30%, we think that additional studies are necessary to clarify if MEK-I can have also a more specific activity and to better identify which patients can benefit more from this combination therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.